Pioglitazone, a drug used in the treatment of diabetes, has been shown to increase adiponectin by acting on PPARγ, which in turn activates AMP kinase, thereby decreasing blood glucose levels (Janani et al., 2014). This evidence concerns the gene PPARG and diabetes mellitus.